Conversely, immunopharmacological research on developing cGAS–STING pathway agonists can help formulate therapies for infectious diseases and cancer, such as anti-pathogen or anti-cancer drugs and adjuvants; however, these drugs should be optimized to augment the desirable effect and should not induce any unwanted effects. The gene discussed is STING1; the disease is cancer.